8-K: INmune Bio Advances Immunotherapies for Alzheimer's, RDEB

INmune Bio Inc. provides an investor presentation detailing late-stage clinical programs for Alzheimer's disease and a rare pediatric inflammatory disease, highlighting regulatory milestones and positive Phase 2 data.

Summary

• INmune Bio is a clinical-stage biotechnology company focused on immunotherapies for inflammation-driven diseases, including rare pediatric inflammatory disease and inflammatory neurologic disease.
• The company's key programs include CORDStrom for Recessive Dystrophic Epidermolysis Bullosa (RDEB), XPro for early Alzheimer's disease, and INKmune for cancer.
• CORDStrom, an allogeneic mesenchymal stromal cell (MSC) platform, completed Phase 2 for RDEB, showing improvements in itch, pain, and systemic symptoms, particularly in younger patients.
• XPro, a selective soluble-TNF inhibitor, completed Phase 2 for early Alzheimer's, demonstrating halted cognitive decline and improved biomarkers (pTau217, GFAP) in an inflammation-enriched patient population, with a strong safety profile (zero ARIA cases).
• The company plans multiple regulatory filings in 2026, including CORDStrom MAA (UK) and BLA (US) submissions, and an End-of-Phase-2 FDA meeting for XPro in Q1 2026.
• INmune Bio reported approximately $30 million in cash and a market capitalization of $50 million as of October 14, 2025, with about 26.5 million shares outstanding.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the advancement of two late-stage programs with promising (though nuanced for XPro) Phase 2 data, clear regulatory pathways, and significant upcoming milestones. The strong safety profile of XPro and the potential for CORDStrom as a first-in-class systemic RDEB therapy are key positives. The primary endpoint miss for XPro in the broad population introduces some caution, but the company's strategy to focus on an enriched population mitigates this.

Positives

• CORDStrom Phase 2 for RDEB showed significant improvements in itch, pain, and systemic symptoms, with observed skin improvement and wound closure, particularly in younger patients.
• CORDStrom has received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the FDA, potentially qualifying for a Priority Review Voucher (PRV).
• XPro Phase 2 for early Alzheimer's demonstrated halted cognitive decline and improved key AD biomarkers (pTau217, GFAP) in an inflammation-enriched patient population.
• XPro exhibited a strong safety profile in Alzheimer's trials with zero cases of amyloid-related imaging abnormalities (ARIA), a common issue with other AD drugs.
• The company has a clear regulatory pathway with multiple near-term milestones, including MAA/BLA submissions for CORDStrom and an End-of-Phase-2 FDA meeting for XPro.
• INmune Bio has a robust and growing intellectual property estate with numerous issued and pending patents across its platforms.
• The company emphasizes a capital-efficient clinical execution model and scalable GMP manufacturing infrastructure.

Negatives

• The XPro Phase 2 MINDFuL trial's primary endpoint was not met in the broader modified Intent-to-Treat (mITT) population due to a lack of cognitive decline in the placebo group, which diluted the overall results.
• Severe and older RDEB patients (over 10 years) did not show changes in their skin within the Phase 2 trial timeframe, although itch and pain improved greatly.

Risks

• Ability to raise capital to fund continuing operations.
• Ability to protect intellectual property rights.
• Impact of any infringement actions or other litigation.
• Competition from other providers and products.
• Ability to develop and commercialize products and services.
• Changes in government regulation.
• Ability to complete capital raising transactions.
• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• No assurance that CORDStrom, XPro1595 (XPro, pegipanermin), and INKmune will be approved by the US Food and Drug Administration (FDA) or any regulatory body.
• Risks and uncertainties relating to the company's ability to produce more drug for clinical trials.

Future Outlook

The company anticipates significant regulatory and clinical milestones in 2026 and 2027. For CORDStrom, this includes MAA submissions in the UK and EU, and a BLA submission in the US, with potential PRV eligibility and launch readiness in 2027. For XPro, an End-of-Phase-2 FDA meeting is scheduled for Q1 2026 to align on regulatory clarity for an enriched patient population, with Phase 3 initiation targeted for 2027. The company aims to continue its capital-efficient development model and leverage its proprietary innate immunology platform.

Management Comments

• Management is focused on modulating the innate immune system to transform inflammation-driven diseases.
• The company is committed to capital-efficient clinical execution and regulatory alignment for its late-stage assets.
• Management believes the pipeline is de-risked and entering a pivotal phase with established safety and biomarker validation.

Industry Context

INmune Bio operates in the highly competitive biotechnology sector, targeting significant unmet medical needs in both rare pediatric diseases (RDEB) and large neurodegenerative markets (Alzheimer's). Its approach of modulating the innate immune system, particularly selective soluble-TNF inhibition for Alzheimer's and MSC therapy for RDEB, positions it uniquely against traditional amyloid-beta or tau-focused AD therapies and existing topical RDEB treatments. The focus on biomarker-enriched populations for Alzheimer's aligns with a growing industry trend towards precision medicine.

Comparison to Industry Standards

• CORDStrom for RDEB is positioned as potentially the first systemic therapy, differentiating it from current topical treatments like Krystal Biotech's VYJUVEK ($750,000/year), Chiesi Farmaceutici's FILSUVEZ ($27,000 per 15 tubes), and Abeona Therapeutics' ZEVASKYN (gene-modified topical skin graft >$3M/treatment/lesion). CORDStrom's anticipated reimbursement is estimated at ~$700,000 per year, making it competitive in the ultra-rare disease market.
• XPro's safety profile, specifically zero cases of ARIA (amyloid-related imaging abnormalities), stands out compared to amyloid-targeting drugs for Alzheimer's disease, which frequently report ARIA as a significant side effect.
• The company's strategy to focus on an inflammation-enriched population for XPro's Phase 3 aligns with the industry's shift towards precision medicine in Alzheimer's, moving beyond broad-population approaches that have often yielded mixed results.

Stakeholder Impact

• Shareholders: Potential for significant value creation through successful clinical development, regulatory approvals, and commercialization of late-stage assets, especially with potential PRV monetization.
• Patients (RDEB): CORDStrom offers hope for the first systemic treatment for an ultra-rare disease with high unmet need, potentially improving quality of life, pain, itch, and reducing long-term risks like squamous cell carcinoma.
• Patients (Early Alzheimer's): XPro offers a novel, safe therapeutic option targeting neuroinflammation, potentially halting cognitive decline and improving biomarkers in a specific patient population.
• Employees: Continued growth and stability as programs advance through pivotal trials and towards commercialization.
• Regulatory Authorities: Engagement through multiple meetings and submissions (FDA, MHRA, EMA) for late-stage assets.

Next Steps

• Q1 2026: XPro End-of-Phase-2 FDA meeting.
• Mid-2026: CORDStrom Market Authorization Application (MAA) submission in the UK.
• Late-2026: CORDStrom Biologics Licensing Application (BLA) submission in the US.
• 2027: XPro Phase 3 initiation for early Alzheimer's disease.
• 2027: CORDStrom PRV Eligibility & Launch Readiness.

Key Dates

Recommendation

The company presents a compelling investment case with two late-stage clinical programs addressing significant unmet medical needs. CORDStrom for RDEB has demonstrated strong Phase 2 results, secured Orphan Drug and Rare Pediatric Disease Designations, and is on a clear path to market with multiple regulatory filings expected in 2026, including potential PRV eligibility. XPro for Alzheimer's, despite a nuanced Phase 2 primary endpoint miss in the broad population, showed clear efficacy and a strong safety profile in an inflammation-enriched subgroup, which is now the focus for a de-risked Phase 3. The company's capital-efficient model, robust IP, and multiple near-term catalysts suggest significant upside potential as these programs advance towards commercialization. The current valuation appears attractive given the late-stage nature of the pipeline and the potential market sizes.

Keywords

Immunotherapy, Alzheimer's Disease, Recessive Dystrophic Epidermolysis Bullosa, RDEB, XPro1595, CORDStrom, Biotechnology, Clinical Trials, Neuroinflammation, Orphan Drug, Rare Pediatric Disease, TNF inhibitor, Mesenchymal Stromal Cells, MSC, Cancer, INKmune